Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Mar 5;14(3):e0213187.
doi: 10.1371/journal.pone.0213187. eCollection 2019.

β-blockers after acute myocardial infarction in patients with chronic obstructive pulmonary disease: A nationwide population-based observational study

Tse-Hsuan Su  1 , Shang-Hung Chang  2 , Chang-Fu Kuo  3 , Pi-Hua Liu  4 , Yi-Ling Chan  1
Affiliations
Observational Study

β-blockers after acute myocardial infarction in patients with chronic obstructive pulmonary disease: A nationwide population-based observational study

Tse-Hsuan Su et al. PLoS One. .

Abstract

Background: Patients with chronic obstructive pulmonary disease (COPD) less often receive β-blockers after acute myocardial infarction (AMI). This may influence their outcomes after AMI. This study evaluated the efficacy of β-blockers after AMI in patients with COPD, compared with non-dihydropyridine calcium channel blockers (NDCCBs) and absence of these two kinds of treatment.

Methods and results: We conducted a nationwide population-based cohort study using data retrieved from Taiwan National Health Insurance Research Database. We collected 28,097 patients with COPD who were hospitalized for AMI between January 2004 and December 2013. After hospital discharge, 24,056 patients returned to outpatient clinics within 14 days (the exposure window). Those who received both β-blockers and NDCCBs (n = 302) were excluded, leaving 23,754 patients for analysis. Patients were classified into the β-blocker group (n = 10,638, 44.8%), the NDCCB group, (n = 1,747, 7.4%) and the control group (n = 11,369, 47.9%) based on their outpatient prescription within the exposure window. The β-blockers group of patients had lower overall mortality risks (adjusted hazard ratio [95% confidence interval]: 0.91 [0.83-0.99] versus the NDCCB group; 0.88 [0.84-0.93] versus the control group), but the risk of major adverse cardiac events within 1 year was not statistically different. β-blockers decreased risks of re-hospitalization for COPD and other respiratory diseases by 12-32%.

Conclusions: The use of β-blockers after AMI was associated with a reduced mortality risk in patients with COPD. β-blockers did not increase the risk of COPD exacerbations.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Patient inclusion and exclusion.
Abbreviations: AMI, acute myocardial infarction; COPD, chronic obstructive pulmonary disease; NDCCB, non-dihydropyridine calcium channel blockers.
Fig 2
Fig 2. Cumulative risk curves of 1-year and overall mortality.
Abbreviations: NDCCB, non-dihydropyridine calcium channel blockers.
Fig 3
Fig 3. Cumulative risk curves of major adverse cardiac events (MACE) in 1 year.
Abbreviations: NDCCB, non-dihydropyridine calcium channel blockers.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Su TH, Chang SH, Chen PC, Chan YL. Temporal trends in treatment and outcomes of acute myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide population-based observational study. J Am Heart Assoc. 2017;6: e004525 10.1161/JAHA.116.004525 - DOI - PMC - PubMed
    1. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339:489–497 10.1056/NEJM199808203390801 - DOI - PubMed
    1. Goldberger JJ, Bonow RO, Cuffe M, Liu L, Rosenberg Y, Shah PK, et al. Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction. J Am Coll Cardiol. 2015;66:1431–1441 10.1016/j.jacc.2015.07.047 - DOI - PMC - PubMed
    1. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr,et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64:e139–228 10.1016/j.jacc.2014.09.017 - DOI - PubMed
    1. Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes. 2011;4:363–371 10.1161/CIRCOUTCOMES.110.957951 - DOI - PubMed

Publication types

MeSH terms

Substances